Marvell's willingness to heavily dilute its shareholders suggests a takeover would probably be an exceptionally good deal for Lumentum. Marvell must have a strong reason to pursue the rumored purchase so aggressively; Lumentum should accept if offered such a deal. x.com 

Buying Lumentum would make Jensen Huang's $1 trillion vision for Marvell seem more realistic, but a roughly $200 billion Marvell would need to dilute shareholders heavily to acquire an approximately $80 billion Lumentum. The deal was still reported as nearing agreement, not completed. x.com 

The photonics-as-AI-bottleneck claim has faded, leaving Lumentum facing more pain before the theme recovers. A large December options node sits at $600; the stock bot targets downside at $650 and $595, with $581 a possible liquidity sweep where smart money would buy instead of rushing in at $650 or $630. Most photonics companies will likely never come back. x.com 

Lumentum's 109% year-on-year growth and sold-out capacity through 2029 make selling its AI optics exposure questionable. Bloomberg reported Marvell is in advanced talks to buy it; the appeal depends on the price, especially when holders of an $80 billion Lumentum would become holders of a $320 billion-plus Marvell growing 37%. x.com 

Marvell looks interesting at less than 30x calendar-2027 EPS against expected 60-70% annual EPS growth, but overpaying for Lumentum could drive its shares lower. Marvell could pay up to $110B, roughly a 30% premium; the stock-versus-debt mix is unclear, and Lumentum holders might own a third of the combined company. If the deal falls apart, Marvell could rise 10-12%. x.com 

Lumentum is a great business, but at $954 its risk/reward is not attractive. Applying 30x to fiscal 2028 non-GAAP EPS of $40 gives a 2027 price target of $1,200, about 26% upside, or roughly 15% after adjusting for execution, financial, technology and supply risks. Reaching it needs on-time manufacturing ramps, sustained pricing power and cash flow without excessive dilution. Lost pricing power plus slipping OCS or laser ramps would break the thesis; a significant dip would offer a better entry. … Show more

A Lumentum deal would put Marvell in a much better competitive position, making its shares an obvious buy here, especially for existing Lumentum shareholders. If the deal breaks, Marvell shares would jump sharply; a moderate premium could mean near-term weakness or sideways trading but would be a great long-term deal. A big premium could push shares down further, though much of that risk is already priced in. x.com  x.com 

Marvell's potential Lumentum acquisition may fail to increase per-share value because the added profits may not cover dilution and financing costs. A simplified calculation using reported market values implies roughly 38%-45% more shares, requiring about 45% more combined net profit to preserve EPS; debt would add interest and repayment pressure. If the price already reflects future growth, a control premium and possible customer concerns add risk. x.com 

Lumentum requires paying up heavily for a company that is not yet making money. Revenue grew 109% year over year, but it trades at about 25 times annualized sales, and it is growing less than memory makers at ten times their valuation. @ZeekTyt cites Lumentum's CEO expecting to supply only about 30% of requested laser demand as CPO and NPO ramp in 2027, with balance around 2029-30. x.com  x.com 

The Lumentum merger makes Marvell's path toward a $1 trillion valuation look clearer if it executes well. Jensen Huang had called Marvell the next $1 trillion company. Lumentum's demand is sold for the next two to three years, though whether that gives Marvell an edge remains an open question. Marvell looks like a long-term opportunity, but the route to building a position is still unclear. x.com